Search

Author/Creator Lu, J

1. 293PD_PRRibociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Zamagni, C; Campone, M; Kudryavcev, I; Brown-Glaberman, U; Cottu, P H; Ring, A; Lu, J; Martín, M; De Laurentiis, M; Zhou, K; Wu, J; Menon, L; Azim, H A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Abdel-Razeq, H; Cottu, P H; Ring, A; De Laurentiis, M; Lu, J; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Menon, L; Martín, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 333PRibociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018)

Authors:
Cardoso, F; Papazisis, K; De Laurentiis, M; Ring, A; Lu, J; Martín, M; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Zarate, J P; Cottu, P H
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗